Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Period	Milestone	Group	Participants
Randomization	STARTED	Telcagepant 140 mg	644
Randomization	STARTED	Telcagepant 280 mg	645
Randomization	STARTED	Placebo	646
Randomization	COMPLETED	Telcagepant 140 mg	573
Randomization	COMPLETED	Telcagepant 280 mg	549
Randomization	COMPLETED	Placebo	555
Randomization	NOT COMPLETED	Telcagepant 140 mg	71
Randomization	NOT COMPLETED	Telcagepant 280 mg	96
Randomization	NOT COMPLETED	Placebo	91
Treatment	STARTED	Telcagepant 140 mg	573
Treatment	STARTED	Telcagepant 280 mg	549
Treatment	STARTED	Placebo	555
Treatment	COMPLETED	Telcagepant 140 mg	444
Treatment	COMPLETED	Telcagepant 280 mg	420
Treatment	COMPLETED	Placebo	399
Treatment	NOT COMPLETED	Telcagepant 140 mg	129
Treatment	NOT COMPLETED	Telcagepant 280 mg	129
Treatment	NOT COMPLETED	Placebo	156

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00483704/flow